Abstracts

Emerging Dolutegravir Resistance Among Children Being Investigated for Treatment Failure in Malawi

Background: Malawi switched from protease inhibitor- (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI)-based paediatric first- and second-line antiretroviral therapy (ART) regimens to dolutegravir-based regimens (DBR) in 2020. By 2022, over 98% of children living with HIV (CLHIV) were on DBR, requiring monitoring of dolutegravir (DTG) resistance. We evaluated the prevalence and patterns of drug resistance…

Safety of Dapivirine Vaginal Ring and Oral PrEP for HIV Prevention in the Second Trimester

Background: Pregnant people are at 3X higher risk of HIV per coital act than nonpregnant people. MTN-042/DELIVER was a phase 3b study of Dapivirine Vaginal Ring (DVR) and oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) to assess safety, adherence, and acceptability when used during pregnancy (NCT03965923). The results of the first two cohorts of women enrolled during…

Community Health Worker-Facilitated Telehealth for Severe Hypertension Care in Kenya and Uganda

Background: Expanding the HIV care model to include HIV status-neutral hypertension treatment can improve cardiovascular disease outcomes; however, individuals with severe hypertension face additional barriers to care, including need for frequent clinic visits to titrate medications. We conducted a pilot study to test whether a clinician-driven, community health worker (CHW) facilitated telehealth intervention would improve…

“Traitor”-Virus-Guided Discovery of Novel Antiviral Factors

Background: Cellular innate defense mechanisms govern the outcome of pathogen exposure. Studies on HIV-1 identified a variety of restriction factors (RFs) that may inhibit different viral pathogens at various steps of their replication cycle. They also revealed, however, that RFs playing roles in HIV-1 transmission and/or are targeted by the viral accessory Vif, Vpr, Vpu…

A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236

Background: The trispecific broadly neutralizing antibody (bNAb) SAR441236 combines the HIV-1 specificities of VRC01 (CD4 binding site), PGDM1400 (V1/V2 glycan binding), and 10E8v4 (membrane proximal external region) into one molecule with amino acid modifications (LS) in the Fc-region for half-life extension. SAR441236 provided complete protection against macaque SHIV challenge but has not been tested in…

Long-Acting Cabotegravir Plus Rilpivirine In Adolescents With HIV: Week 24 IMPAACT 2017(MOCHA) Study

Background: Long-acting (LA), intramuscular (IM) cabotegravir (CAB) + rilpivirine (RPV) constitutes the first LA combination antiretroviral treatment (ART) regimen for people with HIV-1. The goal of the ongoing IMPAACT 2017 study (MOCHA [More Options for Children and Adolescents]; NCT03497676) is to evaluate the safety, tolerability, and pharmacokinetics (PK) of this LA combination in virologically suppressed…

Emerging Dolutegravir Resistance in Lesotho

Background: Since 2018, the World Health Organization has recommended dolutegravir- (DTG-) based antiretroviral therapy (ART) as the preferred regimen for most people with HIV. Most African countries have thus shifted from non-nucleoside transcriptase inhibitor- (NNRTI-) to DTG-based ART, often without requiring prior viral suppression and without access to resistance testing in case of viremia. National…